Kureshi C, Dougan S
Cancer Cell. 2024; 43(1):15-35.
PMID: 39672170
PMC: 11841838.
DOI: 10.1016/j.ccell.2024.11.011.
Paillassa J, Maitre E, Belarbi Boudjerra N, Madani A, Benlakhal R, Matthes T
Cancers (Basel). 2024; 16(12).
PMID: 38927891
PMC: 11201647.
DOI: 10.3390/cancers16122185.
Niu L, Jang E, Chin A, Huo Z, Wang W, Cai W
Sci Adv. 2024; 10(16):eadk7695.
PMID: 38640236
PMC: 11029804.
DOI: 10.1126/sciadv.adk7695.
Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B
Front Immunol. 2023; 14:1188049.
PMID: 37256141
PMC: 10225594.
DOI: 10.3389/fimmu.2023.1188049.
Gargiulo E, Giordano M, Niemann C, Moussay E, Paggetti J, Morande P
Front Oncol. 2023; 13:1122699.
PMID: 36968995
PMC: 10031020.
DOI: 10.3389/fonc.2023.1122699.
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.
Vitali L, Merlini A, Galvagno F, Proment A, Sangiolo D
Biomedicines. 2022; 10(10).
PMID: 36289890
PMC: 9599827.
DOI: 10.3390/biomedicines10102628.
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies.
Lutz E, Agarwal Y, Momin N, Cowles S, Palmeri J, Duong E
Proc Natl Acad Sci U S A. 2022; 119(36):e2205983119.
PMID: 36037341
PMC: 9457244.
DOI: 10.1073/pnas.2205983119.
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
Yao C, Zhang T, Wu T, Brugarolas J
Clin Cancer Res. 2022; 28(23):5013-5020.
PMID: 35819272
PMC: 9835201.
DOI: 10.1158/1078-0432.CCR-21-2372.
Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine.
Bohn J, Dietrich S
Cancers (Basel). 2022; 14(4).
PMID: 35205704
PMC: 8869886.
DOI: 10.3390/cancers14040956.
Drug-based therapeutic strategies for COVID-19-infected patients and their challenges.
Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S
Future Microbiol. 2021; 16:1415-1451.
PMID: 34812049
PMC: 8610072.
DOI: 10.2217/fmb-2021-0116.
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman R, Arons E
Blood Rev. 2021; 51:100888.
PMID: 34535326
PMC: 8418384.
DOI: 10.1016/j.blre.2021.100888.
Next-Generation Immunotherapies to Improve Anticancer Immunity.
Shi Y, Tomczak K, Li J, Ochieng J, Lee Y, Haymaker C
Front Pharmacol. 2021; 11:566401.
PMID: 33505304
PMC: 7831045.
DOI: 10.3389/fphar.2020.566401.
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy.
Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M
Acta Pharm Sin B. 2020; 10(11):2156-2170.
PMID: 33304783
PMC: 7714989.
DOI: 10.1016/j.apsb.2020.04.004.
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U
Blood Adv. 2020; 4(15):3699-3707.
PMID: 32777066
PMC: 7422123.
DOI: 10.1182/bloodadvances.2020002160.
Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity.
Lohmann B, Silginer M, Picard D, Schneider H, Remke M, Roth P
Neurooncol Adv. 2020; 2(1):vdaa043.
PMID: 32642697
PMC: 7212887.
DOI: 10.1093/noajnl/vdaa043.
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Paillassa J, Cornet E, Noel S, Tomowiak C, Lepretre S, Vaudaux S
Blood Cancer J. 2020; 10(5):62.
PMID: 32461544
PMC: 7253459.
DOI: 10.1038/s41408-020-0328-z.
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.
Berentsen S
Front Immunol. 2020; 11:590.
PMID: 32318071
PMC: 7154122.
DOI: 10.3389/fimmu.2020.00590.
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Carlson R, Flickinger Jr J, Snook A
Toxins (Basel). 2020; 12(4).
PMID: 32283684
PMC: 7232517.
DOI: 10.3390/toxins12040241.
Outcome of hairy cell leukemia patients treated with cladribine - a 10-year single-center experience in Pakistan.
Zahid M, Mehdi M, Ali N
Hematol Transfus Cell Ther. 2019; 41(2):134-138.
PMID: 31084763
PMC: 6517679.
DOI: 10.1016/j.htct.2018.08.006.
Current role of interferon in hairy cell leukemia therapy: a timely decision.
Silva Junior W, Teixeira L, Rocha V, Buccheri V
Hematol Transfus Cell Ther. 2019; 41(1):88-90.
PMID: 30793110
PMC: 6371201.
DOI: 10.1016/j.htct.2018.04.004.